Virtual Pancreas System Reaches Optimum Diabetes Targets at Lower Cost Compared to Standard Intensive Care

Presentation Number: MON 276
Date of Presentation: April 3rd, 2017

Saad Sakkal*
Metabolic Care Center, Mason, OH

Abstract

Achieving targets in diabetes care is still an elusive dream, less the 14% of people with Diabetes are able to achieve all targets together. A system useful for all stakeholders is an IT application which makes treatment effective, corrects strategic dosing of insulin and oral medications, and cutting cost to achieve the triple aim of optimum HgA1c/glucose variability, averting hypoglycemia or weight gain. The system adjusts all medications doses and insulin pump setting on daily, weekly or monthly basis l, but what is the cost effectiveness of such system compared to the guidelines accepted provider mode of care?

Hypothesis and design: This tool is now cloud based, reachable by a mobile phone or internet as a Virtual Pancreas System with embedded metabolic simulator. We compared the value index by finding how much money ($) is spent on improving HgA1c by %1 in three months for standard intensive care(SIC) Vs Virtual Pancreas System (VPS) care using the cheapest generic drugs , or any insulin available, and counted the glucose strips needed.

Results:

1) VPS lowered HgA1c by absolute value of 2.3% and relative value of %2.7 when compared to standard care , which is better than many newer medications percent(DPP4: 0.5, SLGT2: 0.8-1, analog insulin: 0.5-1, Glargine300: 0.44, Liraglutide 0.8-1, Dulaglutide: 1.08, inhaled insulin: 0.21).

2) VPS needed only 14 glucose tests/month to get the optimum control needed, a much lower number than the 120 tests recommended monthly for type 1 patient with savings close to 80%, and less than the 60/month for type 2 as often recommended.

3) The diabetes care value index was: $106 per %1 HgA1C drop for VPS, $580 for DDP4, $400 for SGLT2, $500 for insulin analog, $600 for Glargine 300, $770 for Liraglutide, $640 for Dulaglutide, $900 for inhaled insulin.

Interpretation:

VPS will save more than $3000/year per patient while improving quality. We need the savings because “The status quo is unsustainable from both a population health standpoint and an economic one. This technology will do more with less, collecting usable data in very efficient manner since all glucose measurements input is available in the cloud for immediate and long term actions: instantly to patients to self-control, to providers to act, locally for communities to plan and virtually for experts and consultants to advice for large scale population management.

Conclusion: Virtual Pancreas System has superior Diabetes Care Value Index compared to any form of Guideline Standard Intensive care at present. VPS could save more than $3000 yearly per patient.

 

Nothing to Disclose: SS